You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Funded Evidence-Informed Regimens

Drug and regimen monographs and information sheets for patients provide information on dosing and administering cancer treatment protocols. They are for general reference and are not meant to replace prescribing information or physician recommendations.

If you have questions about ST-QBP funding on our website, please visit our Frequently Asked Questions page.

Find enhanced Regimen Patient Information Sheets, created in collaboration with patient and family advisors.


6 Items
Cancer Type: Genitourinary, Prostate     
Intent: Palliative
ODB - General Benefit
  • flutamide
Oct 2016
Cancer Type: Skin, Melanoma     
Intent: Adjuvant, Curative
New Drug Funding Program
    Interferon - Melanoma
Jan 2017
Cancer Type: Hematologic, Myeloproliferative Neoplasms (MPNs)     
Intent: Palliative
Nov 2017
Cancer Type: Hematologic, Leukemia - Chronic Myeloid (CML)     
Intent: Palliative
Dec 2017
Cancer Type: Hematologic, Leukemia - Hairy Cell     
Intent: Palliative
ODB Limited Use
    interferon alfa-2b - For hairy cell leukemia and Kaposi's Sarcoma
Dec 2017
Cancer Type: Hematologic, Lymphoma - T-cell     
Intent: Palliative
Drugs Used:
interferon alfa-2b (Unfunded),
zidovudine (Unfunded)
Oct 2017